Teva Raises 2026 Revenue Outlook as Three Brands’ Combined Sales Gain 33%

Teva Pharmaceutical Industries raised its 2026 revenue outlook Tuesday after combined third-quarter sales from AUSTEDO, AJOVY and UZEDY grew 33% in local currency to about $1.1 billion.

The company lifted its full-year revenue range to $16.7 billion to $17 billion, from $16.5 billion to $16.85 billion. The quarter ended Sept. 30.

AUSTEDO generated $751 million in third-quarter revenue, up 21% year over year. AJOVY brought in $269 million, up 61%, while UZEDY generated $85 million, up 96%.

Teva also raised its 2026 revenue forecasts for all three brands. The AUSTEDO range increased to $2.55 billion to $2.65 billion from $2.45 billion to $2.6 billion. AJOVY’s forecast rose to $930 million to $960 million from $850 million to $870 million, and UZEDY’s moved to $290 million to $310 million from $270 million to $290 million.

In July, Teva had projected about $3.7 billion in combined 2026 revenue from the three brands, roughly 17% growth from the prior year at the midpoint.

Companywide third-quarter revenue fell 2% year over year to $4.395 billion in both U.S. dollars and local currency. Lower global generics sales, primarily amid increased U.S. competition for lenalidomide capsules, offset growth in the three brands.

The non-GAAP operating-income outlook now tops out at $3.9 billion, down from $4 billion, while its lower end remains $3.8 billion. Its adjusted EBITDA range now runs from $4.23 billion to $4.43 billion, compared with $4.23 billion to $4.53 billion previously. Both updated ranges include $870 million in acquired in-process research and development charges.

“Our strong third-quarter performance is another clear demonstration of Pivot to Growth in action and how far Teva has come,” Teva President and CEO Richard Francis said.

Teva released its results at 7 a.m. ET (12:00 UTC) Tuesday, Nov. 3, ahead of an 8 a.m. ET conference call. The event appeared in TokenPost’s Nov. 3 earnings schedule.